The pharmaceutical industry is often seen as an expensive activity that requires considerable R&D investments with no guaranties of return. Success in these activities could be measured by the number of clinical trials (new or diversified indications) resulting from such investments as the more trials you can initiate the bigger the likelihood to deliver successful products. Some companies are better than others in converting the R&D budgets into Proof of Concept and new IP. Cross Indication Research is one of their secret weapon.
Based on real examples, learn how Cross Indication Research can support diversification of the indication space during drug discovery and development but also convert “old” compounds into new interesting therapeutic areas.
This approach is always based on in-depth understanding of the compound´s mode of action (MoA) together with hypotheses on the potential role of respective MoAs in the pathogenesis of different diseases. Proven activity of the compound´s MoA in respective disease models (including studies allowing human estimated dose predictions) can help boost your ROI by defining early clinical strategies, accelerating smart Proof of Concept while generating new IP.
Interested in learning how to maximize your R&D budget with Cross Indication Research?
In this 45-minute presentation, Dr. Ekkehard May, Head of Cross Indication Research, and Dr. Charlotte Kopitz, Head of Therapeutic Research, will cover:
• Indication diversification parallel value chain
• Life cycle Management of drugs
• Drug repurposing activities
• Biomarker-based identification of tumor patients
• Live Q&A session
[Can't join?] Don't worry, register anyway, the slides and recording will be sent to you after the webinar.